和誉-B(2256.HK):专注小分子差异化研发 核心资产匹米替尼待商业化

平安证券
Apr 10, 2025

平安观点:2024 年公司首次实现全年盈利,启动新一轮股东回购计划再次彰显企业经营信心。公司成立于2016 年,致力于差异化小分子创新药物开发,于2021 年在港交所上市。截至目前公司旗下共有19 款肿瘤产品管线,其中12 款候选药物已进入临床开发阶段。凭借着强大的研发实力和丰富的管理运营经验,公司先后与礼来、默克、艾力斯等国内外知名药企达成合作。2024 年公司首次实现全年盈利,净利润达2830...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10